Key result
Alström syndrome is linked to progressive diffuse fibrosis with myocardial T1 increasing ~22 ms annually.
Why the study?
Alström syndrome is characterized by early cardiomyopathy with diffuse interstitial fibrosis, but longitudinal changes in fibrosis and its impact on cardiac function are not well defined.
Observational (n=30)
No
Mean Difference: 21.8 (95% CI 17.4–26.1)
p-value: p=<0.001
Background Alstrom syndrome (ALMS) is a rare ciliopathy characterised by early onset insulin resistance, obesity, and dyslipidaemia and is a model for diseases that have huge social, health and economic impact. Dilated cardiomyopathy develops in the majority, with high rates of morbidity and mortality, the definitive feature of which is the presence of coarse replacement fibrosis and diffuse myocardial fibrosis (DIF). The pathogenesis of heart failure is thought to involve fibroblast accumulation and expansion of the extracellular matrix with excess protein deposition, leading to distorted organ architecture and impaired contractile function. Consecutive adults with genetically proven ALMS attending the National Centre for Rare Disease in Birmingham, England were studied. All patients underwent serial CMR, echocardiography and venous blood sampling following standard clinical practice, with computed tomography coronary angiography (CTCA) performed to assess severity of CAD. The aims of this study were: 1) to evaluate longitudinal changes in DIF by cardiovascular magnetic resonance tissue characterization in ALMS; 2) to examine whether changes in DIF are associated with alteration in systolic or diastolic function; and 3) to evaluate the frequency and severity of coronary artery disease as a confounder for progression of ischaemic versus non-ischaemic fibrosis. Results In total, 30/32 adults (63% male; 67% White British) participated. The median age at first scan was 21.3 years (interquartile range: 19.0-32.6) and participants were followed for a maximum of 67 months. Only 4 patients had flow limiting disease on post-mortem, invasive or CTCA. Mid short axis myocardial T1 times, myocardial extracellular volume, and left ventricular mass increased significantly over time, by an average of 21.8ms (95% CI 17.4 – 26.1; p<0.001), 0.011 (0.006 – 0.016, p<0.001), and 2.8 g/m 2 (1.9 – 3.7; p<0.001) per year, respectively. These changes were not associated with significant deterioration in myocardial structure or function. Conclusions This is the first comprehensive longitudinal study demonstrating progression of DIF in ALMS over time, although no structural or functional consequences were noted within a median three and a half years’ follow up. Further study is warranted to define whether DIF is a by-stander or the driver to impaired contractile function, heart failure and death.
No takes yet. Share an insight, caveat, or question.
Baig et al. (2020) conducted an observational in Alström syndrome (n=30). Alström syndrome (disease progression) vs. Baseline (within-subject comparison) was evaluated on Annual change in mid short axis myocardial T1 time (MD 21.8, 95% CI 17.4-26.1, p=<0.001). In adults with Alström syndrome, mid short axis myocardial T1 times increased significantly by an average of 21.8 ms per year (p<0.001), indicating progressive diffuse interstitial fibrosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: